Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelica Fasolo

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Pharmaceutical Design|April 6, 2012
Targeting mTOR pathways in human malignanciesAngelica Fasolo, Cristiana Sessa
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2009
Translational research in phase I trialsAngelica Fasolo, Cristiana Sessa
Expert Opinion on Investigational Drugs|February 9, 2011
Current and future directions in mammalian target of rapamycin inhibitors developmentAngelica Fasolo, Cristiana Sessa
Expert Opinion on Investigational Drugs|October 17, 2008
mTOR inhibitors in the treatment of cancerAngelica Fasolo, Cristiana Sessa
Nature Clinical Practice. Oncology|December 25, 2008
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancerGabriella Mariani, Angelica Fasolo, Elena De Benedictis, et al.
Clinical Breast Cancer|November 10, 2006
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy studyGabriella Mariani, Fausto Petrelli, Milvia Zambetti, et al.
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal AntibodiesDiego Tosi, Yassine Laghzali, Marie Vinches, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3Fabrice André, Sara Hurvitz, Angelica Fasolo, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Design|April 6, 2012
Targeting mTOR pathways in human malignanciesAngelica Fasolo, Cristiana Sessa
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2009
Translational research in phase I trialsAngelica Fasolo, Cristiana Sessa
Expert Opinion on Investigational Drugs|February 9, 2011
Current and future directions in mammalian target of rapamycin inhibitors developmentAngelica Fasolo, Cristiana Sessa
Expert Opinion on Investigational Drugs|October 17, 2008
mTOR inhibitors in the treatment of cancerAngelica Fasolo, Cristiana Sessa
Nature Clinical Practice. Oncology|December 25, 2008
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancerGabriella Mariani, Angelica Fasolo, Elena De Benedictis, et al.
Clinical Breast Cancer|November 10, 2006
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy studyGabriella Mariani, Fausto Petrelli, Milvia Zambetti, et al.
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal AntibodiesDiego Tosi, Yassine Laghzali, Marie Vinches, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3Fabrice André, Sara Hurvitz, Angelica Fasolo, et al.
Pageof 2